On Friday, Integer Holdings (NYSE:ITGR) stock received a reiterated Buy rating and a $137.00 price target from CL King, despite reporting mixed third-quarter results. The company's revenue for the quarter was $431.4 million, falling short of both the firm's projection of $434.3 million and the consensus estimate of $440.6 million. This discrepancy was partly due to the reclassification of the Electrochem business to discontinued operations, which was not fully accounted for in the consensus.
Integer's earnings per share (EPS) for the quarter, however, exceeded expectations at $1.43, compared to a consensus estimate of $1.36 and the firm's estimate of $1.39. This beat was attributed to higher-than-anticipated gross margins and lower research and development (R&D) spending, along with a reduced tax rate.
Organic growth for the quarter was reported at 4.3%, which was below the firm's expectation of 6.4%. The company saw varying performance across its segments, with Cardio & Vascular sales picking up pace, while Cardiac Rhythm Management & Neuromodulation slowed, and Advanced Surgical, Orthopedics & Portable Medical experienced a decline.
Looking ahead, Integer updated its full-year 2024 forecast, now expecting revenues to range between $1,707 million and $1,727 million, which indicates an increase of 10% to 11%. This is a slight uptick from the previous forecast of 9% to 11% growth. The revised outlook includes an anticipated 7% to 8% organic growth, up from the earlier range of 6% to 8%.
For the fourth quarter of 2024, the company anticipates sequential sales growth driven by new product launches, increased guidewire capacity, and growth from emerging PMA customers. The adjusted EPS forecast has been raised to $5.24 to $5.43, up from the previous range of $5.07 to $5.49.
Integer is set to host an earnings call at 9:00 am ET, and the firm anticipates that the discussion will primarily focus on the company's top-line performance. The firm also suggests that any potential stock price weakness following the call could present a buying opportunity.
The firm's $137 price target for Integer is based on a price-to-earnings (P/E) multiple of 22.8 times the firm's fiscal year 2025 EPS estimates of $6.00. The report also outlines key risks to achieving this price target, including supply chain challenges, integration of acquisitions, expansion of manufacturing facilities, and the risk of key customers moving production in-house.
In other recent news, Integer Holdings Corporation has reported a robust performance in its third-quarter earnings call, with a 9% year-over-year sales growth, reaching $431 million, and a 17% increase in adjusted operating income. The company also announced key leadership changes and the divestiture of the Electrochem business.
In recent developments, Integer Holdings has adjusted its 2024 sales growth outlook to 10%-11% and raised its midpoint profit and EPS projections. The company anticipates a 20% increase in adjusted operating income and a 16% growth in adjusted EPS for 2024. Integer's adjusted EBITDA is forecasted between $358 million and $368 million, an 18% to 21% year-over-year rise.
Despite slight deceleration in organic growth to 4% for Q3 due to lower-than-expected CRM demand and minor disruptions from Hurricane Helene, Integer remains confident in its growth strategy, anticipating a combined sales growth of 29% and a 56% increase in adjusted operating income over 2023 and 2024. The company is also expecting accelerated organic growth in Q4, especially in the Cardio & Vascular and Neuromodulation segments.
InvestingPro Insights
To complement the analysis of Integer Holdings (NYSE:ITGR), recent data from InvestingPro provides additional context to the company's financial position and market performance. As of the latest available data, Integer Holdings boasts a market capitalization of $4.25 billion, reflecting its significant presence in the medical technology sector.
InvestingPro data shows that Integer has demonstrated strong revenue growth, with a 10.07% increase over the last twelve months as of Q3 2024. This aligns with the company's updated full-year forecast mentioned in the article, which projects revenue growth of 10% to 11%. The company's profitability is also noteworthy, with an adjusted operating income of $221.36 million and an operating income margin of 12.53% for the same period.
Two relevant InvestingPro Tips highlight Integer's market position:
1. The stock is trading near its 52-week high, which corroborates the positive outlook maintained by analysts like CL King.
2. Integer has been profitable over the last twelve months, supporting the firm's optimistic EPS forecasts.
These insights reinforce the article's discussion of Integer's financial performance and future prospects. For investors seeking a deeper understanding of Integer Holdings, InvestingPro offers 8 additional tips that could provide valuable context for investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.